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Abstract
Introduction: The search for and creation of drugs with dermatoprotective and metabotropic activity is one of the 
priorities of modern diabetology. Synthetic organophosphorus compounds with no anticholinesterase activity, to which 
Dimephosphone belongs to, deserve great attention in this respect.
Materials and Methods: Experiments included 355 white non-linear male mice (18-34 g) and 799 male rats (150–305 
g). The dermatoprotective activity (DPA) of Dimephosphone regarding the survival of a skin graft was studied against 
the background of normoglycemia, as well as against the background of experimental diabetes complicated by hy-
percholesterolemia. The study of microhemodynamics in the skin was performed using laser Doppler flowmetry. The 
effects on metabolic processes and the antioxidant system were studied by determining the levels of glucose, urea, 
creatinine, total bilirubin, total cholesterol, triglycerides, total protein, albumin, globulin, catalase, malondialdehyde, 
superoxide dismutase, glutathione reductase, glutathione and glutathione peroxidase.
Results: Dimephosphone has a pronounced DPA in conditions of reduced blood circulation against the background 
of normoglycemia and experimental (alloxan) diabetes complicated by exogenous hypercholesterolemia. By DPA, in 
most cases against the background of normoglycemia Dimephosphone exceeds Actovegine, is comparable to or inferior 
to Trental and Mexidol, and is more significant in terms of the therapeutic width than all the drugs taken for comparison.
Discussion: According to the obtained data , DPA of Dimephosphone may be due to its ability to exhibit significant va-
sodilating, antihypoxic, antioxidant, antiaggregant, membrane-stabilizing, anti-acidotic, antimicrobial and other prop-
erties and also to exert a normalizing effect on carbohydrate, protein, lipid and energy metabolism
Conclusion: Dimephosphone can be recommended for further preclinical and clinical studies in the form of various 
dosage forms, as well as in a combination therapy for metabolic disorders.
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Introduction
Diabetes mellitus (DM) is one of the serious socially sig-
nificant diseases characterized by a high prevalence rate, 
a tendency to an increased frequency and severity of com-
plications, and, thus, high disability and patient mortality 
rates (Vasan et al. 2012). To date, there are more than 175 
million patients with diabetes in the world, and this num-
ber is expected to increase to 300 million by 2025.
Diabetes can cause a number of major complications, 
among which micro- and macro-angiopathies are quite 
frequent: changes in small vessels (capillaries, venules, 
arterioles) are specific for diabetes, and vascular lesions 
of medium and large vessels are regarded as manifesta-
tions of early and widespread atherosclerosis (Schlienger 
2013). Microangiopathy is most frequently localized in 
eyes (retinopathy), kidneys (nephropathy) and periphe-
ral nerves (neuropathy), whereas the macroangiopathies 
are localized in the heart (IHD, myocardial infarction), 
brain (acute and chronic impairment of cerebral circu-
lation) and lower extremities (diabetic foot, gangrene) 
(Galenko-Yaroshevsky and Tegay 2016, Levy and Zeich-
ner 2012, Roustit et al. 2016). In addition, diabetes of-
ten leads to the development of hypoxic states, impaired 
blood clotting and cellular immunity, aggravation of in-
flammatory processes, slow and complex wound healing 
(Domingueti et al. 2016)
It is generally recognized that the activation of free ra-
dical oxidation processes is important in the pathogenesis 
of diabetes (Faria and Persaud 2017, Shah and Brown-
lee 2016, Wada and Nakatsuka 2016). This fact served 
as the basis for the use of antioxidant drugs (Tocopherol, 
α-lipoic acid, Nicotinamide, Mexidol, etc.) in the com-
plex treatment of the relevant category of patients (Gupta 
et al. 2012).
According to this, the most important task of modern 
pharmacology is the search for, the creation of and in-
troduction into healthcare practice of highly active drugs 
that can selectively affect the main pathogenetic links of 
diabetes and ensure the prevention and correction of its 
vascular complications (Zimmet and Bloomgarden 2012).
Synthetic organophosphorus compounds with no 
anticholinesterase activity, capable of exhibiting pron-
ounced metabotropic properties, deserve great attention 
in this respect. Dimephosphone (1,1-dimethyl-3-oxo-
butyl-phosphonic acid dimethyl ester), which has low 
toxicity and multifunctional therapeutic properties: an-
tioxidant, antihypoxic, antiaggregant, anti-inflammato-
ry, wound-healing, membrane-stabilizing, vasodilating, 
immunocorrective, bacteriostatic and others (Rodina and 
Moiseeva 2011, Valeeva et al. 2010, 2011) belong to this 
class. At present, the use of multi-target drugs (with se-
veral types of pharmacological activity) is quite relevant, 
as it makes it possible to achieve a higher level of clinical 
effect with fewer side effects, when compared with mo-
no-target drugs (Lera and Ganesan 2016).
To date, there is a large arsenal of drugs for the tre-
atment of diabetic foot syndrome (hypoglycemic drugs, 
B vitamins, antioxidants, antihypoxants, analgesics, anti-
platelet drug, anticoagulants, antiseptics, broad-spectrum 
antibiotics, etc.), but many of them do not always meet 
the requirements imposed on them: they can cause va-
rious side effects, and sometimes do not show a proper 
therapeutic effect, which makes a surgical intervention 
necessary, including skin-plastic surgery (autodermop-
lasty, plastics with local tissues, combined skin plastics), 
up to a high limb amputation at the level of compensated 
blood flow.
Given the complexity and variety of complications 
arising from diabetes, it is very important to create new, 
more effective and less toxic drugs designed to improve 
the efficacy of skin-plastic surgery for DM. Based on this, 
it seemed appropriate to investigate the possible derma-
toprotective activity (DPA) of Dimephosphone under 
conditions of experimental diabetes and exogenous hy-
percholesterolemia.
Materials and methods
The studies were carried out in accordance with the re-
quirements of GOST ISO/IEC 1704-2009, GOST R ISO 
5725-2002 and The Rules of Laboratory Practice ap-
proved by Order № 708n of the Ministry of Healthcare 
and Social Development of the Russian Federation of 
August 23, 2010, in compliance with The European Con-
vention for the Protection of Vertebrates Used for Expe-
riments or Other Scientific Purposes (Directive 2010/63/
EU). The experiments were conducted in accordance with 
The Guidelines for Pre-clinical Study of Medicinal Pro-
ducts (2012).
The experiments included 355 white non-linear male 
mice (weighing 18–34 g) and 799 male rats (weighing 
150–305 g) which had passed the quarantine and were 
kept in the standard vivarium conditions.
The effect of Dimephosphone and comparison drugs 
Actovegine, Trental and Mexidol with intravenous (iv) 
administration on the survival of the pedicle skin flap 
(SF) was studied on anesthetized (urethane 1100 and 
1000 mg/kg, intraperitoneally, ip) white nonlinear male 
mice and male rats in a wide range of doses (Fig. 1).
Evaluation of the results of studying the effect of sub-
stances on the survival of SF was performed in mice 24 
hours, and in rats – 72 hours after the surgery, using the 
following gradation: vastly increases (VsI; more than 
50%), moderately increases (MI; from 18 to 50%), slight-
ly increases (SI; from 15 to 18%).
The effect of Dimephosphone and comparison drugs 
Actovegine, Trental and Mexidol with their combined lo-
cal and iv administration on the survival of pedicle SF 
was studied in the experiments on anesthetized (urethane 
1100, ip) white non-linear male mice. SF was treated (by 
irrigation or lubrication) with Dimephosphone (15% solu-
tion for external use), Actovegine (5% officinal ointment), 
Trental (2% solution prepared on isotonic NaCl solution 
from an officinal concentrate) and Mexidol (5% solution). 
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Then, the test drugs (ampouled solutions) were adminis-
tered at increasing doses twice iv (with a 4-hour interval): 
Dimephosphone – 12.5, 25, 50 and 75 mg/kg, Actovegine 
– 50, 100, 150 and 200 mg/kg, Trental – 2, 5, 5, 7.5 and 
10 mg/kg, and Mexidol – 20, 30, 40 and 50 mg/kg. In the 
control experiments, an isotonic solution of NaCl was used 
at the rate of 10 ml/kg. Evaluation of the results of studying 
the effect of substances on SF survival was carried out 24 
hours after modeling the SF using the following gradation: 
VsI (more than 50%), MI (from 18 to 50%), SI (from 15 to 
18%), no increase, NI (±15%).
Investigation of the influence of Dimephosphone 
and comparison drugs Actovegin and Trental with their 
combined local and ip administration on SF engraft-
ment was carried out in the experiments on anesthetized 
(urethane 1000, ip) white non-linear male rats. The test 
substances were used immediately after the SF simulation 
and over the next 19 days: initially SF was treated with 
Dimephosphone (irrigated with 15% solution for external 
use), Actovegine (smeared with 5% official ointment) and 
Trental (irrigated with 2% solution prepared with isotonic 
NaCl solution, from the official concentrate), and then the 
drug was administered (as ampouled solutions) at doses 
of 110, 410 and 25 mg/kg, corresponding to the effective 
average doses (ED0.5) determined for rats when studying 
the effect of these drugs on pedicle SF survival. An iso-
tonic solution of NaCl (control) was also applied locally 
(by irrigation) and ip (10 ml/kg/day). Each experimental 
group (3) of animals included 10 rats, control – 12. Eva-
luation of the SF survival rate was performed on the 5th, 
10th, 15th and 20th day of the study. The area of SF necrosis 
(wound defect) after a scab coming off was measured pla-
nimetrically and expressed in %.
The effect of Dimephosphone on the pedicle SF sur-
vival against the background of experimental diabetes 
mellitus (EDM), complicated by exogenous hyperchole-
sterolemia (EHC) was carried out in experiments on an-
esthetized (urethane 1000, ip) white non-linear male rats. 
The animals were randomized into 4 groups:
1 – intact rats – 50 individuals (outcome);
2 – animals in which type 1 EDM (Mozheiko 2013) 
and EHC were simulated, for which Alloxan tetrahydrate 
(Fluka-Sigma, Germany) was administered ip once at a 
dose of 135 mg/kg. After 2 weeks (after stable EDM was 
formed) and throughout the next 14 days, an oil choles-
terol emulsion was injected at a dose of 40 mg/kg (in 0.5 
ml of vegetable oil); In order to enhance peroxide stress, 
Ergocalciferol was added to it at the rate of 12,500 U/kg 
– 50 individuals (control);
3 – animals without EDM and EHC, which had recei-
ved Dimephosphone at a dose of 100 mg/kg/day subcuta-
neously (sc) for 14 days – 40 individuals;
4 – rats with EDM and EHC, to which, simultaneously 
with the cholesterol emulsion, Dimephosphone was injec-
ted at a dose of 100 mg/kg/day sc – 50 individuals. During 
the preparation of the animals for the study of Dimep-
hosphone DPA, their mortality in groups 1, 2, 3 and 4 was 
0, 18, 2.5 and 8%, respectively.
To assess the state of carbohydrate and lipid meta-
bolism in EDM, complicated with EHC and the use of 
Dimephosphone, one part of rats from groups 1, 2 and 
4 (8 animals from each) on the 29th day of the experi-
ment, after 16-17 hours of starvation, were euthanized by 
decapitation under ether anesthesia. Then, the animals’ 
blood serum was used to determine the glucose content 
(by the glucose oxidase method using the standard Glyu-
koza-FKD reagents, Russia), total cholesterol (TC), trig-
lycerides (TG), and high-density lipoprotein cholesterol 
(HDLС) (by means of standard reagents by Olvex on an 
analyzer OP-901, Finland). Very low density lipoprotein 
(VLDL) and low density lipoprotein (LDL) cholesterol, 
as well as atherogenic index (AI) was calculated by the 
generally accepted formulas.
The influence of Dimephosphone on microhemody-
namics in the skin was carried out in the experiments on 
white non-linear male rats. The animals were divided into 
2 groups. The rats of the first group served as a control 
(n=7); they were administered ip a 0.2 ml isotonic NaCl 
solution once a day. The animals of the second group 
(n=15) were ip administered with Dimephosphone at a 
dose of 100 mg/kg, which, according to the data obtain-
ed in the present research, is close to the average effec-
tive dose of this drug (113.8 mg/kg, iv), which causes a 
50% dermatoprotective effect when simulating SF in the 
back of rats. The study of changes in the parameters of 
blood microcirculation (BM) in the skin was performed 
by laser Doppler flowmetry (LDF) by means of a laser 
blood flow analyzer LAKK-02 (Lazma, Russia) using 
the LDF 2.20.0.507WL software. The basal blood flow 
was determined within 6 minutes before and 2 hours af-
ter administration of isotonic NaCl solution (control) and 
Dimephosphone. As parameters analyzed by the LDF 
method, non-oscillatory indices of the basal blood flow 
were recorded: perfusion index (perfusion units; M – the 
steady component of perfusion), average standard devia-
tion; coefficient of variation (%) (Krupatkin and Sidorov 
2013). To identify the mechanisms underlying hemody-
namic changes, the amplitude of blood flow oscillations 
of different frequency ranges was determined using the 
wavelet analysis of the LDF signal. Oscillations in the 
Figure 1. Scheme of skin flap modeling in rats.
Galenko-Yaroshevsky PA et al.: Effects of  Dimephosphone on skin survival ...44
range of 0.0095-0.02 Hz were taken as endothelial waves 
(Krupatkin and Sidorov 2013). Oscillations in the range 
of 0.07–0.15 Hz were interpreted as myogenic oscillati-
ons caused by the periodic activity of smooth muscle cells 
(vasomotion). Oscillations in the range of 0.02–0.046 Hz 
were considered as neurogenic oscillations, reflecting 
sympathetic regulatory activity (Hoffman et al. 1990). 
High-frequency oscillations included respiratory (0.15–
0.4 Hz) and pulse (0.8–0.16 Hz) waves (Hoffman et al. 
1990, Krupatkin and Sidorov 2013).
In-depth studies of the effect of Dimephosphone on 
the metabolic profile, indicators of oxidative stress and 
antioxidant systems under conditions of EDM complica-
ted by EHC, and the presence of the pedicle SF was con-
ducted in experiments on non-linear white male rat. EDM 
and EHC were created by daily intravenous administra-
tion of Alloxan tetrahydrate (Fluka-Sigma, Germany) to 
the animals at a dose of 50 mg/kg for 14 days and for the 
next 14 days by injecting oil cholesterol emulsion at a 
dose of 40 mg/kg (0.5 ml of vegetable oil). The studies 
were performed on 2 groups of animals, each of which 
included 3 subgroups consisting of intact (10 and 10 in-
dividuals), control (isotonic NaCl solution was injected; 
8 and 9 individuals) and experimental (Dimephosphone 
100 mg/kg/day was injected sc for 14 days; 9 and 10 indi-
viduals). In the first group, the indicators of glucose, urea, 
uric acid, creatinine, TC, TG, total protein, albumin, glo-
bulin, total bilirubin, and the activity of alanine aminot-
ransferase (ALT) and aspartate aminotransferase (AST) 
were determined, with calculating the de Ritis ratio (AST/
ALT), and in the second – the indicators of catalase, ma-
lonic dialdehyde (MDA), superoxide dismutase (SOD), 
glutathione reductase (GR), glutathione and glutathione 
peroxidase (GPO).
The effect of Dimephosphone on the rats’ heparin plas-
ma metabolic profile (concentration of glucose, urea, uric 
acid, creatinine, TC, TG, total protein, albumin, globulin, 
total bilirubin, ALT and AST activity with calculating the 
de Ritis ratio) was studied using Dia-Sys (Germany) and 
Cormay (Poland) standard commercial kits, and a Targa 
BT 3000 (Italy) automatic biochemical analyzer (when 
determining bilirubin).
The effect of Dimephosphone on indicators of oxidative 
stress (MDA) and antioxidant systems (SOD, catalase, 
GR, GPO, glutathione). The concentration of MDA was 
determined by the method of K. Yagi (1976), the activity 
of SOD – by a degree of inhibition of nitro-blue tetrazoli-
um reduction by superoxide anion-radical generated in 
vitro in the xanthine-xanthine oxidase system, catalase on 
a Thermo Electron Evolution spectrophotometer (USA), 
while GR – by the Hosoda and Nakamura method (Hoso-
da and Nakamura 1970). The concentration of glutathione 
and its system components was also determined using a 
Thermo Electron Evolution spectrophotometer (USA).
Statistical processing of research results. The signifi-
cance of differences in mean values was calculated using 
Student’s t-test. The reliability of intergroup differences 
was assessed using the Mann-Whitney U-test at p<0.05. 
For all substances, ED0.5 (Rajevski 1976) corresponding 
to an increase in the SF survival by 50% was determin-
ed graphically, and therapeutic indices, or the therapeutic 
width (TW – LD50/ED0.5), were calculated, using personal 
computer software developed at the Department of Phar-
macology of Kuban State Medical University of the Mi-
nistry of Healthcare of the Russian Federation, licensed 
Microsoft® Office® Professional Plus 2013 and STATIS-
TICA-8.0 software.
Results
Comparative DPA of Dimephosphone, Actovegine, 
Trental and Mexidol when they are administered iv.
Influence on the pedicle SF survival in experiments on 
mice. Dimephosphone (25, 50, and 75 mg/kg) on the 2nd 
day after a twofold (with an interval of 4 hours) iv injec-
tion shows a dose-dependent DPA. When using the drug 
at total doses of 50, 100 and 150 mg/kg, the length of the 
necrotic part (LNP) of SF was 55.0, 41.7 and 21.1% ver-
sus 69.4% in the control. The difference in the length of 
the necrotic parts (DLNP) of the control and experimental 
groups of animals was 14.1, 27.8 and 48.3%, the survi-
ving part (SP; when comparing the necrotic parts of the 
SF in these groups) – 20.8, 40.0 and 69.6%, respectively. 
And at the first 2 doses (50 and 100 mg/kg), Dimephosp-
hone caused an MI survival rate of SF, in the last (150 mg/
kg) – a VsI survival rate (Fig. 2). The revealed regulari-
ty of Dimephosphone DPA made it possible to calculate 
ED0.5, which amounted to 113.3 mg/kg.
Actovegine (100, 150, and 200 mg/kg), Trental (5, 
10, and 15 mg/kg) and Mexidol (30, 40, and 50 mg/kg), 
taken as reference drugs, also showed a dose-dependent 
DPA in the accepted experimental conditions. When 
administering Actovegin at the total doses of 200, 300 and 
400 mg/kg, the LNPs of SF amounted to 53.3, 35.0 and 
17.0% versus 66.5% in the control. The DLNPs of SF in 
the control and experimental groups of animals were 13.2, 
31.5 and 49.5%, SP – 16.8, 47.4 and 74.4%, respectively. 
At the same time, when administered at the first dose (200 
mg/kg), Actovegin showed SI survival rates of SF, at the 
second (300 mg/kg) – MI, and at the third (400 mg/kg) – 
VsI; ED0.5 of Actovegine was 313.2 mg/kg.
When Trental was used at the total doses of 10, 20 and 
30 mg/kg, the LNPs of SF were 47.0, 36.7, and 21.0% 
versus 65.0% in the control. The DLNPs of SF in the 
control and experimental groups of animals were 18.0, 
28.3 and 44.0%, SP – 27.7, 43.5 and 67.7%, respectively. 
At the same time, when administered at the first two doses 
(10 and 20 mg/kg), Trental caused MI of SF survival, at 
the last dose (30 mg/kg) – VsI; ED0.5 was 21.9 mg/kg.
In cases of using Mexidol at the total doses of 60, 
80 and 100 mg/kg, the LNPs of SF were 43.9, 32.5 and 
25.0% versus 56.5% in the control. The DLNPs of SF in 
the control and experimental groups of animals were 12.6, 
24.0 and 31.5%, SP – 22.3, 42.5 and 55.8%, respectively. 
When administered at the first two doses (60 and 80 mg/
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kg), Mexidol induced MI for SF survival, at the latter 
(100 mg/kg) – VsI. However, it should be noted that the 
DPA of Mexidol at the doses of 80 and 100 mg/kg did not 
have statistically significant differences (p>0.05). On this 
basis, ED0.5 Mexidol, equal to 91.7 mg/kg, is conditional.
When comparing the indicators of DPA (ED0.5), 
acute toxicity (according to LD50 for mice in case of ip 
injection) and TW of the test drugs, it was found that by 
the first indicator Dimephosphone was 2.8 times superior 
to Actovegin, close to Mexidol, and 5.2 times inferior to 
Trental; by the second indicator – 9.5 and 7.0 times more 
significant (less toxic) than Trental and Mexidol, and 
almost comparable to Actovegin; by the third indicator 
– 5.6, 1.8 and 2.9 times superior to Mexidol, Trental and 
Actovegin, respectively (Table 1).
Thus, in experiments on mice, Dimephosphone by 
DPA is 2.8 times superior to Actovegine, close to Mexi-
dol, and 5.2 times inferior to Trental; and by TW it is 5.6, 
1.8 and 2.9 times more significant than Mexidol, Trental 
and Actovegine.
The effect on the pedicle SF survival in experiments on 
rats. Dimephosphone (25, 50 and 75 mg/kg), Actovegine 
(100, 150 and 200 mg/kg), Trental (5, 10 and 15 mg/kg) 
and Mexidol (30, 40 and 50 mg/kg) 3 days after a twofold 
(with an interval of 4 h) intravenous injections also sho-
wed a dose-dependent DPA. When using Dimephospho-
ne at the total doses of 50, 100 and 150 mg/kg, LNPs of 
SF were equal to 48.2, 36.7 and 24.7% versus 66.5% in 
the control. DLNPs of SF in the control and experimental 
groups of animals were 18.3, 29.8 and 41.9, SP – 27.5, 
44.8 and 62.9%, respectively; and at the first 2 doses (50 
and 100 mg/kg) the drug induced MI for SF survival, and 
at the latter (150 mg/kg) – VsI (Fig. 3); ED0.5 was 113.8 
mg/kg.
Based on the data obtained, it was of interest to inves-
tigate DPA of Dimephosphone at higher doses of 200 and 
250 mg/kg. It turned out that the drug at these doses also 
showed DPA, but it did not differ much from that in the 
study at a dose of 150 mg/kg: at doses of 200 and 250 mg/
kg, LNPs of SF were 25.6 and 26.1% against 69.2% in 
Figure 2. The ratio of the necrotic and surviving parts of the pedicle SF (in the back) in mice 1 day after a twofold intravenous 
injection of isotonic NaCl (control) and Dimephosphone with an interval of 4 h at total doses of 50, 100 and 150 mg/kg
Note. On the ordinate axis – the length of the SF, taken as 100%, on the abscissa axis – isotonic NaCl solution and the total dose 
of the drug. Bar graphs: shaded (dark) area – necrotic part of SF, light area – surviving part, wavy area – confidence boundaries 
(÷) at p<0.05; the numbers on the right side of the columns are the indices of the surviving part of SF when using drugs compared 
to the control. *(p <0.05)
Table 1. DPA of Dimephosphone, Actovegine, Trental and Mexidol (1 day after double intravenous drug injection) when modeling 
SF in the mice back area
Drug DPA Acute toxicity (mice)1 TW
ED0.5, mg/kg Relative LD50, mg/kg Relative Absolute Relative
Dimephosphone 113.3 0.8 3000.02 7.0 26.5 5.6
Actovegine 313.2 0.3 2854.63 6.6 9.1 1.9
Trental 21.9 4.2 316.04 0.7 14.4 3.1
Mexidol 91.7 1.0 430.05 1.0 4.7 1.0
Note: DPA – dermatoprotective activity; TW – therapeutic width  
1ip injection. 2Arbuzov et al. (1968). 3Gorovoy (1991). 4Tegay (2004). 5Gavrilova (2001).
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the control, DLNPs of SF in the control and experimental 
groups of animals and SP of SF were 43.6 and 63.0, 43.2 
and 62.4%, respectively, and corresponded to VsI grada-
tion.
In cases of applying Actovegine at the total doses of 
200, 300 and 400 mg/kg, LNPs of SF were 46.0, 36.9 and 
30.5% versus 62.9% in the control. DLNPs of SF in the 
control and experimental groups of animals were 17.0, 
26.1 and 32.5%, SP – 27.0, 41.4 and 51.6%, respective-
ly; and at the first 2 doses (200 and 300 mg/kg) the drug 
caused MI of the SF survival, and at the latter (400 mg/
kg) – VsI; ED0.5 was 408.2 mg/kg.
Like the case of Dimephosphone, it was of interest to 
investigate DPA of Actovegine at higher doses of 500 and 
600 mg/kg. It is established that at these doses the drug 
also had DPA; however, it was close to that when using 
the drug at a dose of 400 mg/kg: at doses of 500 and 600 
mg/kg, LNPs of SF were 27.8 and 25.0% versus 64.4 % 
in the control. DLNPs of SF in the control and experi-
mental group and the SP of SF were 36.6 and 56.8, 39.4 
and 60.3%, respectively, which corresponded to VsI gra-
dation.
When using Trental at the total doses of 10, 20 and 
30 mg/kg, LNPs of SF were 47.5, 35.8 and 30.2% versus 
68.9% in the control. DLNPs of SF in the control and ex-
perimental groups of animals amounted to 21.4, 33.0 and 
38.6%, and SP – 31.0, 47.9 and 56.1%. At the same time, 
when administered at the first 2 doses (10 and 20 mg/kg), 
the drug induced MI for SF survival, and at the last (30 
mg/kg) – VsI; ED0.5 was 24.0 mg/kg.
In cases of using Mexidol at the total doses of 60, 80 
and 100 mg/kg, LNPs of SF were 46.7, 37.9 and 28.2% 
versus 66.0% in the control. At the same time, DLNPs of 
SF in the control and experimental groups of animals were 
19.3, 28.2 and 37.8%, and SP – 29.2, 42.6 and 57.3%. At 
the first 2 doses (60 and 80 mg/kg), the drug caused MI 
for SF survival, and at the latter (100 mg/kg) – VsI; ED0.5 
was 90.0 mg/kg.
The comparison of the DPA of the test substances in 
the experiments on rats showed that Dimephosphone by 
its activity (ED0.5) was 3.6 times superior to Actovegin, 
but 4.7 and 1.3 times inferior to Trental and Mexidol, and 
by TW it was 3.8, 2.0 and 5.5 times more significant than 
Actovegine, Trental and Mexidol, respectively (Table 2).
Thus, in the experiments on rats, Dimephosphone by 
DPA is 3.6 times superior to Actovegine, and 4.7 and 1.3 
times inferior to Trental and Mexidol, and by TW it is 
3.87, 2.0 and 5.5 times more significant than Actovegine, 
Trental and Mexidol, respectively.
Comparative DPA of Dimephosphone, Actovegine, 
Trental and Mexidol with their combined local and pa-
renteral use.
The effect on the survival of pedicle SF in experiments 
on mice (iv injection). Studies of the effect of Dimephosp-
hone, Actovegine, Trental and Mexidol on the survival 
rate of pedicle SF in mice 24 hours after combined local 
and iv application showed that all the drugs have a do-
se-dependent DPA. Thus, with irrigating SF with a 15% 
solution of Dimephosphone and its intravenous injection 
at the total doses of 25, 50, 100 and 150 mg/kg, LNPs 
of SF were 48.2, 42.5, 29.4 and 22.9% versus 59.0% in 
control. DLNPs of SF in the control and experimental 
groups of animals were 10.8, 16.5, 29.6 and 36.1%, SP 
of SF – 18.3, 28.0, 50.1 and 61.3 %. The drug in the first 
combined (local and iv) administrtion showed SI survival 
of SF, in the second – MI, and in the third and fourth – 
Figure 3. The ratio of the necrotic and surviving parts of the pedicle SF (in the back area) in rats 3 days after double iv administration 
of isotonic NaCl solution (control) and Dimephosphone with an interval of 4 hours at total doses of 50, 100, 150, 200 and 250 mg/kg
Note. On the ordinate axis – the length of the SF, taken as 100%, on the abscissa axis – isotonic NaCl solution and the total dose 
of the drug. Bar graphs: shaded (dark) area – necrotic part of SF, light – surviving part, wavy – confidence boundaries (÷) at 
p<0.05; the numbers on the right side of the columns are the indices of the surviving part of SF when using drugs compared to 
the control. * (p<0.05)
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VsI. Based on the fact that the dermatoprotective effects 
of Dimephosphone in the last two combined applications 
did not have statistically significant differences (p>0.05), 
the data of the first three combined applications were used 
to calculate its ED0.5 (Fig. 4); ED0.5 was 100.1 mg/kg.
When 5% Actovegine ointment was used to irrigate 
SF and Actovegine was administered iv at the total doses 
of 100, 200, 300 and 400 mg/kg, LNPs of SF were 55.5, 
44.6, 33.9 and 21.4% versus 61.1% in control. DLNPs 
of SF in the control and experimental groups of animals 
were 5.6, 16.6, 27.2 and 39.8%, and SP of SF – 9.2, 27.1, 
44.5 and 65.1%. In its first combined use, the drug indu-
ced NI in the survival rate of SF, in the second and third 
– MI, in the fourth – VsI; ED0.5 was 323.2 mg/kg.
In experiments with the use of Trental by irrigating SF 
with its 2% solution and its iv administration at the total 
doses of 5, 10, 15 and 20 mg/kg, LNPs of SF were 51.5, 
37.2, 29.0 and 21.2% versus 58.3% in control. DLNPs 
of SF in the control and experimental groups of animals 
were 6.8, 21.2, 29.3 and 37.3%, and SP of SF – 11.7, 36.2, 
50.3 and 63.9%, and in the first combined use, the drug 
had NI impact on the SF survival rate, in the second indu-
ced MI, in the third and fourth – VsI; ED0.5 was 15 mg/kg.
When a 5% solution of Mexidol was used to irrigate 
SF and Mexidol was administered iv at the total doses of 
40, 60, 80 and 100 mg/kg, LNPs of SF were 56.2, 42.3, 
29.6 and 22.3% versus 51.5 % in control. DLNPs of SF 
in the control and experimental groups of animals were 
-5.1, 8.8, 21.5 and 28.7%, and SP of SF was -9.9, 17.2, 
42.1 and 56.3%. In the first combined use, the drug had 
NI impact on the survival rate of SF, and in the second, 
third and fourth, respectively, – SI, MI and VsI; ED0.5 
was 91.8 mg/kg.
Comparison of DPA (according to ED0.5), acute toxi-
city (according to LD50 for mice with ip injection) and 
TW of the test drugs revealed that by the first indicator 
Table 2. Dermatoprotecting activity of Dimephosphone, Actovegine, Trental and Mexidol (1 day after double intravenous drug 
administration) when modeling SF in the back area in rats
Drug DPA Acute toxicity (mice)1 TW
ED0.5, mg/kg Relative LD50, mg/kg Relative Absolute Relative
Dimephosphone 113.8 0.8 3000.02 7.0 26.4 5.5
Actovegine 408.2 0.2 2854.63 6.6 7.0 1.5
Trental 24.0 3.8 316.04 0.7 13.2 2.8
Mexidol 90.0 1.0 430.05 1.0 4.8 1.0
Note: DPA - dermatoprotective activity – TW - therapeutic width  
1ip injection. 2B.A. Arbuzov et al. (1968). 3Gorovoy (1991). 4Tagay (2004). 5Gavrilova (2001).
Figure 4. The effect of Dimephosphone, Actovegine and Trental on the engraftment of free SF in experiments on rats.
Note. On the ordinate axis – the area of SF necrosis on the 5th, 10th, 15th and 20th day after the operation; on the abscissa axis – iso-
tonic NaCl solution, Dimephosphone (D), Actovegine (A), Trental (T).
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Dimephosphone is 3.2 times superior to Actovegine, clo-
se to Mexidol and 6.7 times inferior to Trental; by the 
second indicator – 9.5 and 7.0 times more significant (less 
toxic) than Trental and Mexidol, and practically compa-
rable to Actovegine; by the third – 6.4, 1.5 and 3.4 times 
superior to Mexidol, Trental and Actovegine, respectively 
(Table 3).
It was also important to compare DPA and TW of 
Dimephosphone, Actovegin, Trental and Mexidol (Table 
3) with the same indicators presented in Table 1, when 
the test drugs were used parenterally (iv injection twice 
with an interval of 4 hours) in the experiments on mice. 
It turned out that only in the combined use of Trental, 
its ED0.5 and TW significantly changed: the first indi-
cator decreased 1.5 times, and the second increased 1.4 
times. As for Dimephosphone, Actovegine and Mexidol, 
in case of their combined use, ED0.5 and TW compared 
with those in case of iv injection did not undergo signi-
ficant changes.
A statistically significant increase in DPA of Trental 
and practically absence of such in Dimephosphone, Ac-
tovegine and Mexidol in their combined local and iv ad-
ministration, unlike in case of solely iv administration 
may be due to a higher rate of absorption and the lipop-
hilicity of Trental when it is applied on SF in contrast to 
the other test drugs.
Thus, in the experiments on mice, Dimephosphone 
and comparison drugs Actovegine, Trental, and Mexidol, 
in their combined application – with a single local and 
double (with an interval of 4 hours) iv administration – 
24 hours after the simulation of a pedicle SF increased 
SF survival. By their DPA, the test drugs can be arranged 
as follows: Trental>Dimephosphone=Mexidol>Actove-
gine, and by TW – Dimephosphone>Trental>Actove-
gin>Mexidol.
Trental, unlike Dimephosphone, Aktovegin and Mexi-
dol, when combined, exhibits a more significant DPA than 
when administered solely iv.
Influence on engraftment of free SF in experiments 
on rats (with ip administration). The areas of SF necro-
sis (wound defect) which appeared after a scab coming 
off) on the 5th, 10th, 15th and 20th days of the study in the 
control (isotonic NaCl solution topically and ip) were 7.6, 
18.8, 10.2 and 4.5%, and with a similar use of Dimep-
hosphone (15% solution topically + ip 110 mg/kg/day), 
Actovegin (5% ointment topically + ip 410 mg/kg/day) 
and Trental (2% solution topically + ip 25 mg/kg/day) – 
1.6, 5.4, 4.5 and 1.4%, 1.4, 5.0, 2.6 and 0.4%, 2.8, 7.8, 6.2 
and 1.6 %, respectively, i.e. compared with the control, 
taken as 100% for all the study periods, SF necrosis under 
the influence of the drugs decreased by 21.1, 28.7, 44.1 
and 31.1%, 18.4, 26.6, 25.5 and 8.9%, 36.8, 41.5, 60.8 
and 35.6%, respectively; in all the study periods, the dif-
ferences between the control and experimental indicators 
were statistically significant (Fig. 3).
When comparing Dimephosphone, Actovegine and 
Trental by their ability to increase the engraftment of free 
SF, it was found that on the 5th and 10th days of the study 
they had no statistically significant differences. On further 
study dates, Actovegine was the leader, which on the 15th 
day increased SF engraftment more significantly than 
Trental and was comparable to Dimephosphone, and on 
the 20th day exceeded both Trental and Dimephosphone 
in this regard (Fig. 4).
Thus, in the experiments on rats, Dimephosphone 
and reference drugs Actovegine and Trental, with local 
and ip administration for 20 days, increased engraft-
ment of free SF and epithelization of the wound defect 
(after a scab coming off) on the 15th and 20th days of the 
study, while the drugs can be arranged in the following 
order: on the 15th day – Actovegine>Trental=Dimep-
hosphone, on the 20th day – Actovegine>Dimephosp-
hone=Trental. Dimephosphone, unlike Actovegine and 
Trental, prevents the development of suppuration in the 
area of free SF.
Investigation of the state of carbohydrate and lipid 
metabolism in EDM complicated by EHC and the use of 
Dimephosphone.
In the blood serum of the control rats, the levels of 
glucose, TC, TG, VLDL and LDL, compared with the 
corresponding indicators of the intact animals, incre-
ase by 226.7, 86.3, 35.6, 33.3 and 94.5%, respectively, 
and HDLC decreases by 57.3%, while AI increases by 
356.3%.
The administration of Dimephosphone to rats (100 
mg/kg/day for 14 days, sc) against the background of 
EDM and EHC had a normalizing effect on the state of 
carbohydrate and lipid metabolism. Thus, the indicator 
of glucose in the serum of rats did not differ much from 
that of the intact animals and was 67.8% lower than the 
Table 3. Comparative DPA of Dimephosphone, Actovegine, Trental and Mexidol 24 hours after the combined single local and dou-
ble (with an interval of 4 hours) iv administration
Drug DPA Acute Toxicity (mice)1 TW 
ED0.5, Mg/kg Relative LD50, mg/kg Relative Absolute Relative
Dimephosphone 100.1 (113.3) 0.9 (0.8) 3000.02 7.0 30.0 (26.5) 6.4 (5.6)
Actovegine 323.2 (313.2) 0.3 (0.3) 2854.63 6.6 8.8 (9.1) 1.9 (1.9)
Trental 15.0 (21.9) 6.0 (4.2) 316.03 0.7 20.0 (14.4) 4.3 (3.1)
Mexidol 91.8 (91.7) 1.0 (1.0) 430.03 1.0 4.7 (4.7) 1.0 (1.0)
Note: In brackets – DPA and TW of the test drugs 24 hours after the double dose (with an interval of 4 hours) iv administratino to 
the mice. 1ip injection. 2Arbuzov et al. (1968). 3Galenko-Yaroshevsky et al. (2003).
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corresponding indicator of the control rats. The indica-
tors of lipid metabolism were characterized by the fol-
lowing changes; the levels of TC, TG, VLDL and LDL 
were close to those of the intact animals (2.29, 0.67, 
0.31 and 1.31 mM/L versus 2.05, 0.59, 0.27 and 1.03 
mM/L, respectively), although they remained statistical-
ly significantly elevated, and when compared with the 
corresponding indicators of the control rats significantly 
– decreased by 40.1, 16.3, 13.8 and 56.8%, respectively. 
The level of HDL in relation to that of the intact animals 
was statistically significantly reduced (0.68 mM/L ver-
sus 0.75 mM/L), and increased by 58.1% compared to 
that in the control rats. AI with respect to that of the in-
tact animals remained statistically significantly elevated 
(2.38 vs. 1.74), and decreased by 70.0% compared with 
the corresponding index of the control rats.
Thus, in EDM complicated by ECH, considerable 
disturbances of carbohydrate and lipid metabolism are 
observed in rats, while Dimephosphone has a significant 
corrective effect on them.
Effect on microhemodynamics in rats’ skin.
In the animals of the control group after the administra-
tion of an isotonic NaCl solution, no significant changes 
in the BM indices in the skin were observed. At the same 
time, with the administration of Dimephosphone, there 
were significant changes in both oscillatory and non-os-
cillatory indices of cutaneous microhemodynamics com-
pared with those obtained in the control group before and 
after the administration of an isotonic NaCl solution to 
the experimental group of rats before the administration 
of Dimephosphone.
Among the oscillatory parameters, the amplitudes of 
endothelial (Ae; by 74%, p<0.05) and neurogenic (An; 
by 57%, p<0.05) genesis increased most significant-
ly relative to the values of these indicators recorded in 
the animals of the control group after administration of 
isotonic NaCl solution. Since Ae is synchronized with 
periodic release of nitric oxide (NO) by the vascular en-
dothelium, an increase in this indicator clearly shows an 
increase in the secretion of NO by the endothelium and, 
as a result, the development of endothelium-dependent 
vasodilation.
An increase in fluctuation amplitudes of LDF-grams in 
the neurogenic range (An), which are associated with adr-
energic effects on the smooth muscle cells (SMC) of arte-
rioles and arteriolar areas of arteriovenular anastomoses, 
reflects a decrease in peripheral resistance in these areas 
of the microbed, resulting in an improvement in nutritive 
blood flow.
In addition to Ae and An, after the administration of 
Dimephosphone, the amplitudes of myogenic rhythms 
(Am; by 24%, p<0.05) reliably increased in relation to 
the values of these indicators recorded in the animals of 
the control group, which reflects a decrease in the tone 
of precapillary sphincters and metarteriols (Stefanovska 
and Bracic 1999). It is known that the rhythms of this 
range are caused by fluctuations in the Ca2+ concentra-
tion through SMC membranes (Stefanovska and Bracic 
1999); therefore, an increase in Am indicates a decrease 
in the tone of the precapillaries due to the development of 
Ca2+-dependent muscular relaxation under the influence 
of Dimephosphone.
Against the background of the stimulation of the ac-
tive components of regulating the skin microcirculation, 
an increase in the amplitudes of pulse oscillations (An, 
by 16%, p<0.05) occurred relative to the values of these 
indicators recorded in the control animals. This indica-
tor reflects the perfusion pressure in microvessels, caused 
both by cardiac output, changes in systolic and diastolic 
pressure, and by the influence of postcapillary resistance 
(Stefanovska and Bracic1999). Consequently, an increase 
in this indicator proves that under the influence of Dimep-
hosphone, the inflow of arterial blood into the micro-bed 
increases.
It is worth noting that Dimephosphone did not signifi-
cantly influence the amplitude of the respiratory rhythms 
(Ar), which are associated with respiratory modulation of 
the venular blood flow and respiratory effects on the vege-
tative support of the heart (Stefanovska and Bracic1999). 
At the same time, the constant level of Ar against the 
background of decreased tone of resistive microvessels 
(increase in Ae, An, Am) and the corresponding increase 
in the blood inflow to the micro-bed (increase in An) re-
flects an increase in the arteriovenous pressure gradient in 
the micro-bed, which indirectly indicates the optimization 
of venular outflow.
These changes in microhemodynamics were reflected 
in the increased non-oscillatory indices of the basal blood 
flow: perfusion rate – by 42% (p<0.05), standard devia-
tion – by 33% (p<0.05) and coefficient of variation – by 
46% (p<0.05) relative to the values of these indicators 
recorded in the animals of the control group, which in-
dicates an increase in blood perfusion and modulation of 
blood flow in all frequency ranges.
Thus, in the experiments on rats, Dimephosphone 
causes changes in the oscillatory and non-oscillatory 
indices of microhemodynamics in the skin, which in-
dicates that it increases perfusion of peripheral tissues 
and modulation of blood flow in the microvessels by 
increasing the functional activity of the endothelium, 
reducing peripheral resistance, increasing blood flow to 
the nutritive microvascular system, and improving the 
venular outflow.
Studies of the effect of Dimephosphone on the meta-
bolic profile, indicators of oxidative stress, antioxidant 
system in the blood of rats with pedicle SF in the back 
area and EDM complicated by EHC.
Effect on carbohydrate, lipid and protein exchanges, 
ALT and AST activity. In the blood of the control ani-
mals, which had been injected with isotonic NaCl solution 
(within 14 days, sc), the levels of glucose, urea, uric acid, 
creatinine, TC, TG, total bilirubin, ALT and AST increased 
statistically significantly compared to the intact animals by 
390.3, 44.7, 10.3, 31.0, 91.1, 44.8, 92.9, 80.7 and 124.0%, 
respectively. The indicators of total protein, albumin and 
globulin decreased by 80.6, 81.0 and 80.1%, respectively.
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The use of Dimephosphone (100 mg/kg/day for 14 
days, sc) in accepted experimental conditions caused nor-
malization of carbohydrate, lipid and protein metabolism 
in rats. Thus, the content of glucose, urea, uric acid and 
creatinine were almost the same as that of the intact ani-
mals and were by 76.8, 23.2, 7.0 and 19.4% lower than 
the corresponding indicators of the control rats.
The levels of TC and TG when using Dimephospho-
ne compared with those of the intact rats were elevated 
(2.27 and 0.66 mm/L versus 2.02 and 0.58 mm/L, res-
pectively), although in the case of TC, these differences 
were statistically insignificant, and in relation to the cor-
responding indicators of the control animals they were 
significantly lower by 41.2 and 21.4%, respectively. The 
idicators of total protein, albumin and globulin compa-
red with those of the intact rats were almost compara-
ble (65.36, 35.24 and 30.12 g/L versus 68.04, 35.23 and 
32.80 g/L, respectively), and in relation to the indicators 
of the control animals, statistically significantly incre-
ased by 19.2, 23.4 and 14.6%. As for the total bilirubin, 
its level compared with that of the intact rats did not 
undergo significant changes (0.15 g/L versus 0.14 g/L), 
and in relation to the control data it significantly decre-
ased by 44.4%.
The activity of ALT and AST in the blood serum of the 
intact animals was 32.4 and 146.5 U/L, and in the blood 
of control ones – 58.6 and 328.2 U/L, respectively, which 
may be due to significant differences (fluctuations) in in-
dividual indicators. This, obviously, affected the de Rit-
tis Ratio, which in the first case was greater than 1 and 
amounted to 4.54, and in the second it turned out to be 
equal to 5.68, i.e. had increased.
After the use of Dimephosphone, the activity of ALT 
and AST compared to that of the intact rats was almost 
comparable (35.2 and 149.7 U/L versus 32.4 and 146.5 
U/L, respectively), and when compared to the control 
indicators, they were statistically significantly lower – 
by 39.9 and 54.4%, respectively. At the same time, the 
de Rittis ratio compared with that of the intact animals 
did not undergo significant changes, while it was statis-
tically significantly lower when compared to that in the 
control rats.
Thus, in the experiments on rats with pedicle SF in the 
back area, EDM and EHC, Dimephosphone has a norma-
lizing effect on carbohydrate, lipid and protein exchanges, 
and also has (judging by the changes in ALT and AST) 
anti-inflammatory, antinecrotic, cardioprotective, and 
possibly hepatoprotective effects.
Discussion
Dimephosphone after double iv injection to mice and rats 
against the background of normoglycemia increases the 
survival rate of pedicle SF in the back area in a dose-de-
pendent manner. In the experiments on mice, by its DPA, 
it exceeds Actovegin, is close to Mexidol, and is inferior 
to Trental; by its TW, it is more significant than Mexi-
dol, Trental and Actovegin. In the experiments on rats, by 
its DPA, it exceeds Actovegine, is inferior to Trental and 
Mexidol; by its TW, it is more significant than Actovegi-
ne, Trental and Mexidol.
In case of the combined local (single) and iv (double) 
administration in the experiments on mice, Dimephosp-
hone increases the survival rate of pedicle SF in the back 
area: by its DPA, it exceeds Actovegine, is comparable 
to Mexidol and inferior to Trental; by its TW, it is more 
significant than all the comparison drugs.
In the experiments on rats, Dimephosphone with repea-
ted (20-day) local and ip administration promotes engraft-
ment of free SF and wound epithelization. By its activity 
on the 15th and 20th days of the study, Dimephosphone 
is comparable to Trental and inferior to actovein. Unlike 
Actovegine and Trental, Dimephosphone, does not cause 
development of suppuration in the area of free SF.
With a single ip administration to rats, Dimephosphone 
increases tissue perfusion and modulation of blood flow 
in the skin microvasculature by increasing endothelial 
functional activity, reducing peripheral resistance, incre-
asing blood inflow to the nutritive microvascular bed and 
improving venular outflow.
Taking into account its ability to promote engraftment 
of free SF under ESD conditions complicated by EHC, 
the DPA mechanism of Dimephosphone may be due to its 
inclusion in various homeostasis links and indirectly, at 
the level of the whole organism, to correct the functioning 
of disturbed local (myogenic and metabolic) and remote 
neurohumoral processes regulating the blood supply to 
the skin. An important role in promoting DPA in Dimep-
hosphone against the background of EDM complicated 
by EHC is also played by its positive effect on carbohy-
drate, protein and lipid exchanges.
Conclusion
The results obtained suggest that Dimephosphone needs 
further studying as a drug that improves skin survival 
in conditions of reduced blood circulation against the 
background of diabetes mellitus, combined with ather-
osclerosis. Since the drug demonstrated a significant 
pharmacological activity in both systemic and topical 
administrations, the development of new dosage forms 
containing Dimephosphone is a promising direction. The 
high activity of the drug in case of metabolic disorders 
makes it possible to recommend it for preclinical studies 
in combination with insulin, oral hypoglycemic agents, 
statins, fibrates, etc.
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